antimicrobial agents
Download
Skip this Video
Download Presentation
Antimicrobial Agents

Loading in 2 Seconds...

play fullscreen
1 / 31

Antimicrobial Agents - PowerPoint PPT Presentation


  • 158 Views
  • Uploaded on

Antimicrobial Agents. Most other drugs to be covered affect body systems to cure imbalance or malfunction E.g. reduce inflammation, relieve pain, etc. Antimicrobials used to inhibit or destroy living organisms which are “uninvited guests” Drugs must harm invader without harming host

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Antimicrobial Agents' - hartwell


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
antimicrobial agents
Antimicrobial Agents
  • Most other drugs to be covered affect body systems to cure imbalance or malfunction
    • E.g. reduce inflammation, relieve pain, etc.
  • Antimicrobials used to inhibit or destroy living organisms which are “uninvited guests”
    • Drugs must harm invader without harming host
    • Notion of selective toxicity
    • Lectures will focus more on interactions between drug and microbe than drug and host.
selective toxicity
Selective toxicity
  • The more distantly related the invader, the more targets available for the drug to hit
    • The less likelihood of toxic side effects.
  • Prokaryotes biochemically least similar
  • Fungi and Protozoa are eukaryotes, so more closely related to humans.
  • Helminths (worms) also animals
  • Viruses use our own cell machinery
  • Cancer cells ARE our cells.
history of antimicrobial therapy
History of Antimicrobial Therapy
  • 1909 Paul Ehrlich
    • Differential staining of tissue, bacteria
    • Search for magic bullet that would attack bacterial structures, not ours.
    • Developed salvarsan, arsenic derivative used against syphilis.

http://www.chemheritage.org/EducationalServices/pharm/antibiot/activity/stain/salvarsa.gif

timeline
Timeline
  • 1929 Penicillin discovered by Alexander Fleming
    • Messy lab, cool damp weather, luck
  • 1940 Florey and Chain mass produce penicillin for war time use, becomes available to the public.
  • 1935 Sulfa drugs discovered
  • 1943 Streptomycin discovered
  • Western civilization fundamentally changed
historical distinctions
Historical distinctions
  • Antibiotics: substances produced by organisms that have inhibitory effects on other organisms.
    • Penicillin, streptomycin
  • Synthetic drugs: produced in a lab.
    • Salvarsan, sulfa drugs
  • Nowadays, most antimicrobials are semi-synthetic
    • Chemically modified versions of natural products
    • Distinction between “antibiotics” and “synthetic drugs slowly being abandoned.
synthetics vs antibiotics
Synthetics vs. Antibiotics
  • Antibiotics generally have a lower MIC
    • Minimum inhibitory concentration
    • Effective a lower doses
  • Better therapeutic index
    • Safer; larger quantity must be administered before harmful side effects occur.

e.g. Ti = LD50 / ED50

where do antibiotics come from
Where do antibiotics come from?
  • Soil dwelling organisms
    • Several species of fungi including Penicillium and Cephalosporium
      • E.g. penicillin, cephalosporin
    • Species of actinomycetes, Gram positive filamentous bacteria
      • Many from species of Streptomyces
    • Also from Bacillus, Gram positive spore formers
    • A few from myxobacteria, Gram negative bacteria
    • New sources explored: plants, herps, fish
antibiotics are common in nature
Antibiotics are common in nature
  • Many are discovered every year, but not all are useful
    • May belong to previously recognized family, so not really new
    • Toxicity to host makes them unusable
    • They may have poor chemical properties
      • Insoluble, unstable, rapidly metabolized
    • No longer effective against resistant organisms
what and why
What and why
  • Antibiotics are secondary metabolites
    • Substances not essential for the growth of the organism
    • Typically produced at onset of stationary phase
      • When growth slows down
    • Production inhibited by presence of nutrients
  • Why do microbes make them?
    • No one is sure
    • Habitat guarding: prevents outsiders from establishing themselves when residents inhibited
bacteriostatic vs bactericidal
Bacteriostatic vs. Bactericidal
  • Antibiotics differ by mode of action
  • Bacteriostatic compounds inhibit the growth of bacteria
    • Holds invaders in check; host immune system does the killing
  • Bactericidal compounds directly kill the bacteria
  • Location and severity of infection affect choice of antibiotic
    • E.g. CNS infection calls for bactericidal treatment.
antibacterial agents
Antibacterial agents
  • There are 5 principle targets for antimicrobial agents to work against bacterial cells
    • Inhibition of cell wall synthesis
    • Inhibition of protein synthesis
    • Attack on cell membranes
    • Disruption of nucleic acid synthesis
    • Interference with metabolism
review and overview of bacterial targets
Review and Overview of Bacterial Targets
  • Bacterial cell walls
    • Except for Mycoplasma and relatives, all bacteria of the Domain Eubacteria possess peptidoglycan
    • Peptidoglycan provides shape and structural support to bacterial cells
    • Bacterial cytoplasm is generally hypertonic compared to their environment
      • Net flow of water: into cell
      • Wall under high osmotic pressure
cell walls continued
Cell walls continued
  • Chemical structure of peptidoglycan contributes to its function
    • Polysaccharide chains composed of 2 alternating sugars, N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM)
    • Cross-linked in 3 dimensions with amino acid chains
    • A seamless, bag-like molecule which resists osmotic pressure
    • A breach in peptidoglycan endangers the bacterium
glycan chains cross linked with amino acids
Glycan chains cross-linked with amino acids
  • G- and G+ vary w/ DAP vs. lysine and at the interbridge.
  • Note the presence of unusual “D” amino acids.
  • Peptides attached to NAM.
peptidoglycan is a 3d molecule
Peptidoglycan is a 3D molecule

Cross links are both horizontal and vertical between glycan chains stacked atop one another.

http://www.sp.uconn.edu/~terry/images/other/peptidoglycan.gif; http://www.alps.com.tw/cht/img/anti-allergy_002.jpg

slide16

There is no molecule similar to peptidoglycan in humans, making drugs that target cell wall synthesis very selective in their toxicity against bacteria.

gram positive gram negative
Gram positive & Gram Negative
  • Gram positive bacteria have a thick cell wall
    • Peptidoglycan directly accessible from environment
  • Gram negative bacteria have a different wall
    • Thin layer of peptidoglycan
    • Surrounded by an outer membrane composed of lipopolysaccharide, phospholipids, and proteins
    • OM is a barrier to diffusion of molecules including many antibiotics
      • Only some antibiotics are that hydrophobic
      • Porins allow passage of only some antibiotics
ribosomes site of protein synthesis
Ribosomes: site of protein synthesis
  • Prokaryotic ribosomes are 70S;
    • Large subunit: 50 S
      • 33 polypeptides, 5S RNA, 23 S RNA
    • Small subunit: 30 S
      • 21 polypeptides, 16S RNA
  • Eukaryotic are 80S Large subunit: 60 S
      • 50 polypeptides, 5S, 5.8S, and 28S RNA
    • Small subunit: 40S
      • 33 polypeptides, 18S RNA
slide20

Differences in structure between prokaryotic and eukaryotic ribosomes make antibiotics that target protein synthesis fairly selectively toxic against bacteria.

other targets
Other Targets
  • Bacterial DNA is negatively supercoiled
    • Supercoiling is maintained by gyrase, a type II topoisomerase.
    • Inhibition of gyrase and type IV topoisomerase interferes with DNA replication, causes cell death
    • Eukaryotic topoisomerases differ in structure
  • Bacterial cell membranes are essentially the same in structure as those of eukaryotes
    • Antibiotics also affect Gram neg. cell walls
    • Anti-membrane drugs are less selectively toxic than other antibiotics
other targets 2
Other Targets-2
  • Metabolic inhibitors
    • Mostly target the folic acid synthesis pathway
    • Many bacteria can and do synthesize a large proportion of needed cofactors
    • Humans require folic acid in the diet (a “vitamin”), thus folic acid synthesizing enzymes are not an available target in humans
      • Selectively toxic
drug selection
Drug selection
  • Identity of infectious agent
    • Many infections viral, antibiotic administration is a dangerous waste.
    • Identification of bacterium provides rational basis for choice
    • Administration depends on severity of situation
    • Choice of drug influenced by location of infection
      • Certain bacteria are more likely at certain anatomical sites, directing “blind” choice
      • Not all drugs reach compartments equally
spectrum
Spectrum
  • When specific testing is not done or delayed, antibiotic with a broad spectrum is administered
    • Broad spectrum antibiotics can penetrate Gram – outer membranes, resist inactivation, etc.
    • Shotgun: better chance of inhibiting pathogen
  • Downsides
    • Normal microbiota found in ecological balance
    • Death of normal microbiota results in overgrowth of native, resistant bacteria (endogenous infection) or allows invasion by outside opportunists.
drug administration
Drug administration
  • Antibiotics administered oral, i.v., i.m.
    • Same caveats apply, i.e. acid instability, delayed absorption with food for oral
    • i.v. gives higher, quicker concentrations, reaches more compartments with sufficient dose quickly
problem sites
Problem sites
  • Endocarditis: fibrin from inflammation
  • CSF because of blood-brain barrier
  • Osteomyelitis
  • Artificial joints, valves
    • biofilms make it difficult for drug to reach target
  • Abscesses: inflammatory barrier restricts access; also bacteria stop growing
  • Intracellular infections
    • Penetration into host cells, not just microbe
host factors and toxicity
Host factors and toxicity
  • Antibiotics have been so successful because of their selective toxicity
    • But “any substance that has a biological effect will have a biological side effect”
  • Allergies and intolerance
    • Immediate and delayed type hypersensitivities when drug acts as a hapten
    • Intolerance: e.g. erythromycin makes me puke.
  • Age: renal function, development, type of pathogen
host factors and toxicity 2
Host factors and toxicity-2
  • Renal
    • Many antibiotics cleared through renal action, so renal function affects dose, choice.
  • Liver: Good hepatic function needed for metabolism of some antibiotics
  • Pregnancy
    • Beware of developmental effects, teratogenesis
  • Host defenses
    • Influences choice of bactericidal vs. bacteriostatic
  • Genetic background, metabolic factors
combination therapy
Combination therapy
  • Generally frowned on by drug people
  • Some valuable reasons why combination therapy is used
    • Synergistic effects between two drugs
    • Polymicrobial infections, e.g. abdominal injuries
    • Avoid or circumvent microbial resistance
antibiotic resistance
Antibiotic resistance
  • Inherent: Outer membrane of Gram negative bacteria, wall-less bacteria.
  • Mutations: change in transport protein, ribosome, enzyme, etc. Normally harmful mutations are selected FOR in the presence of antibiotic.
  • Plasmids: through conjugation, genetic information allowing cell to overcome drug.

http://www.mun.ca/biochem/courses/3107/

images/Stryer/Stryer_F32-13.jpg

mechanisms of drug resistance
Mechanisms of drug resistance
  • Alteration of target: active site of enzyme changes, ribosome changes.
  • Alteration of membrane permeability: transport protein changes, drug no longer enters; drug that does enter is actively pumped out.
  • Enzymatic destruction of drug: penicillinases (beta lactamases)
  • “End around” inhibitor: bacteria learns to use new metabolic pathway, drug no longer effective.
ad